Title : Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.

Pub. Date : 2003 Apr

PMID : 12722021






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The combination of gemcitabine, paclitaxel, and trastuzumab in patients with HER2-positive metastatic breast cancer with no prior chemotherapy in the metastatic setting produced a response rate of 71% and median response duration of 11 months. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens